Joan Merrill
Oklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joan Merrill as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05306873 · Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic LupusNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Systemic Lupus Erythematosus · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Characterization and Biorepository CoreP30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · fiscal years 2023 to 2026 · $341,000 awarded in 2026Same name and institution; not confirmed by an ID
- CLINICAL COREP20RR015577 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · fiscal years 2009 · $64,085 awarded in 2009Same name and institution; not confirmed by an ID
- Polymorphisms of Antiphospholipid Protein AntigensR01HL071305 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · fiscal years 2002 to 2005 · $392,250 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:23 UTC. The ranking covers the 200 most relevant of 113 PubMed records, and a shared surname and initials can bring in a namesake. All 113 on PubMed
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis Rheum · 20111,282 citationsRCR 35.1
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Arthritis Rheum · 20101,054 citationsRCR 26.7
- Combined oral contraceptives in women with systemic lupus erythematosus.N Engl J Med · 2005904 citationsRCR 23.4
- Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N Engl J Med · 2005808 citationsRCR 21.3
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.Arthritis Rheumatol · 2017681 citationsRCR 24.9
- The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.Ann Intern Med · 2005497 citationsRCR 12.7
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.Arthritis Rheum · 2009433 citationsRCR 11.1
- Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.Ann Rheum Dis · 2016400 citationsRCR 14.1
- Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.N Engl J Med · 2006348 citationsRCR 9.9
- 313 citationsRCR 10.1